The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment
Open accessAbstract
Dravet syndrome is a catastrophic pediatric epilepsy with severe intellectual disability, impaired social development and persistent drug-resistant seizures. One of its primary monogenic causes are mutations in Nav1.1 (SCN1A), a voltage-gated sodium channel. Here we characterize zebrafish Nav1.1 (scn1Lab) mutants originally identified in a chemical mutagenesis screen. Mutants exhibit spontaneous abnormal electrographic activity, hyperactivity and convulsive behaviours. Although scn1Lab expression is reduced, microarray analysis is remarkable for the small fraction of differentially expressed genes (~3%) and lack of compensatory expression changes in other scn subunits. Ketogenic diet, diazepam, valproate, potassium bromide and stiripentol attenuate mutant seizure activity; seven other antiepileptic drugs have no effect. A phenotype-based screen of 320 compounds identifies a US Food and Drug Administration-approved compound (clemizole) that inhibits convulsive behaviours and electrographic seizures. This approach represents a new direction in modelling pediatric epilepsy and could be used to identify novel therapeutics for any monogenic epilepsy disorder. Scn1a encodes a voltage-gated sodium channel and mutations in this gene are implicated in epilepsy. Baraban et al. find that the compound clemizole is effective in blocking epilepsy-like seizures zebrafish with an Scn1adevelopmental mutation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yu, F. H., Mantegazza, M., Westenbroek, R. E., Robbins, C. A., Kalume, F., Burton, K. A., Spain, W. J., McKnight, G. S., Scheuer, T., & Catterall, W. A. (2006) · Nature Neuroscience · doi:10.1038/nn1754 · Cited by 1,173
Ogiwara, I., Miyamoto, H., Morita, N., Atapour, N., Mazaki, E., Inoue, I., Takeuchi, T., Itohara, S., Yanagawa, Y., Obata, K., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5270-06.2007 · Cited by 879
Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expression
Baraban, S. C., Taylor, M. R., Castro, P. A., & Baier, H. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.11.031 · Cited by 687
Self-citationAutistic-like behaviour in Scn1a+/− mice and rescue by enhanced GABA-mediated neurotransmission
Han, S., Tai, C., Westenbroek, R. E., Yu, F. H., Cheah, C. S., Potter, G. B., Rubenstein, J. L., Scheuer, T., de la Iglesia, H. O., & Catterall, W. A. (2012) · Nature · doi:10.1038/nature11356 · Cited by 643
Modern antiepileptic drug development has failed to deliver: Ways out of the current dilemma
Löscher, W., & Schmidt, D. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03024.x · Cited by 590
Key factors in the discovery and development of new antiepileptic drugs
Bialer, M., & White, H. S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2997 · Cited by 542
The spectrum of SCN1A-related infantile epileptic encephalopathies
Harkin, L. A., McMahon, J. M., Iona, X., Dibbens, L., Pelekanos, J. T., Zuberi, S. M., Sadleir, L. G., Andermann, E., Gill, D., Farrell, K., et al. (2007) · Brain · doi:10.1093/brain/awm002 · Cited by 531
Catterall, W. A., Kalume, F., & Oakley, J. C. (2010) · The Journal of Physiology · doi:10.1113/jphysiol.2010.187484 · Cited by 428
Mulley, J. C., Scheffer, I. E., Petrou, S., Dibbens, L. M., Berkovic, S. F., & Harkin, L. A. (2005) · Human Mutation · doi:10.1002/humu.20178 · Cited by 351
Cheah, C. S., Yu, F. H., Westenbroek, R. E., Kalume, F. K., Oakley, J. C., Potter, G. B., Rubenstein, J. L., & Catterall, W. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211591109 · Cited by 336
Cited by
Zebrafish as tools for drug discovery
MacRae, C. A., & Peterson, R. T. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4627 · Cited by 1,204
Zebrafish as an emerging model for studying complex brain disorders
Kalueff, A. V., Stewart, A. M., & Gerlai, R. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.12.002 · Cited by 1,182
Zebrafish models for translational neuroscience research: from tank to bedside
Stewart, A. M., Braubach, O., Spitsbergen, J., Gerlai, R., & Kalueff, A. V. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2014.02.011 · Cited by 704
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials
Patton, E. E., Zon, L. I., & Langenau, D. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00210-8 · Cited by 567
Kroll, F., Powell, G. T., Ghosh, M., Gestri, G., Antinucci, P., Hearn, T. J., Tunbak, H., Lim, S., Dennis, H. W., Fernandez, J. M., et al. (2021) · eLife · doi:10.7554/elife.59683 · Cited by 347
Metabolic Dysfunction and Oxidative Stress in Epilepsy
Pearson-Smith, J., & Patel, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112365 · Cited by 276
Fontana, B. D., Mezzomo, N. J., Kalueff, A. V., & Rosemberg, D. B. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.004 · Cited by 272
Advancements in zebrafish applications for 21st century toxicology
Garcia, G. R., Noyes, P. D., & Tanguay, R. L. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.009 · Cited by 271
15 years of zebrafish chemical screening
Rennekamp, A. J., & Peterson, R. T. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2014.10.025 · Cited by 264
Animal models in epilepsy research: legacies and new directions
Grone, B. P., & Baraban, S. C. (2015) · Nature Neuroscience · doi:10.1038/nn.3934 · Cited by 259
Self-citationDevelopmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum
Guerrini, R., Conti, V., Mantegazza, M., Balestrini, S., Galanopoulou, A. S., & Benfenati, F. (2023) · Physiological Reviews · doi:10.1152/physrev.00063.2021 · Cited by 196
Preclinical Animal Models for Dravet Syndrome: Seizure Phenotypes, Comorbidities and Drug Screening
Griffin, A., Hamling, K. R., Hong, S., Anvar, M., Lee, L. P., & Baraban, S. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00573 · Cited by 103
Self-citationRepurposing drugs to treat cardiovascular disease in the era of precision medicine
Abdelsayed, M., Kort, E. J., Jovinge, S., & Mercola, M. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00717-6 · Cited by 93
Real-life survey of pitfalls and successes of precision medicine in genetic epilepsies
Balestrini, S., Chiarello, D., Gogou, M., Silvennoinen, K., Puvirajasinghe, C., Jones, W. D., Reif, P., Klein, K. M., Rosenow, F., Weber, Y. G., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-325932 · Cited by 49
Strachan, L. R., Stevenson, T. J., Freshner, B., Keefe, M. D., Miranda Bowles, D., & Bonkowsky, J. L. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx249 · Cited by 46
Molecular subtyping and improved treatment of neurodevelopmental disease
Stessman, H. A. F., Turner, T. N., & Eichler, E. E. (2016) · Genome Medicine · doi:10.1186/s13073-016-0278-z · Cited by 25
Metadata
- Authors
- Baraban, S. C., Dinday, M. T., & Hortopan, G. A.
- Venue
- Nature Communications
- Published
- 2013-09-03
- Volume
- 4
- Issue
- 1
- Pages
- 2410-2410
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W1984701456
- Cited by
- 436
- References
- 42
- FWCI
- 18.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.